BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism

Brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) promote the development and maintenance of neural circuits. Alterations in these factors might contribute to autism spectrum disorder (ASD). We asked whether serum BDNF, proBDNF, and IGF-1 levels are altered in an ASD...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-08, Vol.12 (1), p.13768-13768, Article 13768
Main Authors: Robinson-Agramonte, Maria de los Angeles, Michalski, Bernadeta, Vidal-Martinez, Belkis, Hernández, Leyanis Ramos, Santiesteban, Mabel Whilby, Fahnestock, Margaret
Format: Article
Language:English
Subjects:
631/378
692/4017
692/699
Autism
Brain-derived neurotrophic factor
Enzyme-linked immunosorbent assay
Humanities and Social Sciences
Insulin
Insulin-like growth factor I
Insulin-like growth factors
multidisciplinary
Neural networks
Science
Science (multidisciplinary)
Serum levels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) promote the development and maintenance of neural circuits. Alterations in these factors might contribute to autism spectrum disorder (ASD). We asked whether serum BDNF, proBDNF, and IGF-1 levels are altered in an ASD population compared to controls. We measured serum BDNF, proBDNF, and IGF-1 immunoreactive protein in boys and girls aged 5–15 years old with mild to moderate ASD and non-autistic controls by ELISA. IGF-1 was increased in ASD serum compared to controls and was correlated with age and with CARS scores. Serum BDNF levels did not differ between groups, however, proBDNF serum levels were decreased in subjects with ASD compared to non-autistic controls. Medicated, but not unmedicated, ASD subjects exhibited lower serum proBDNF levels compared to controls, while neither IGF-1 nor BDNF levels differed between treatment groups. These data support the involvement of proBDNF and IGF-1 in the pathogenesis and treatment of autism.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-17503-6